Lung Cancer

1

A cross-modal 3D deep learning for accurate lymph node metastasis prediction in clinical stage T1 lung adenocarcinoma

Zhao, Xingyu, Wang, Xiang, Xia, Wei, Li, Qiong, Zhou, Liu, Li, Qingchu, Zhang, Rui, Cai, Jiali, Jian, Junming, Fan, Li, Wang, Wei, Bai, Honglin, Li, Zhen, Xiao, Yi, Tang, Yuguo, Gao, Xin, Liu, Shiyuan

Journal:

Lung Cancer

Year:

2020

File:

PDF, 2.62 MB

2020

2

A modified T categorization for part-solid lesions in Chinese patients with clinical stage I Nonâsmall cell lung cancer

Deng, Jiajun, Zhao, Mengmeng, Wang, Tingting, She, Yunlang, Wu, Junqi, E, Haoran, Gao, Jiani, Sun, Xiwen, Jiang, Gening, Zhu, Yuming, Xie, Dong, Chen, Chang

Journal:

Lung Cancer

Year:

2020

File:

PDF, 2.39 MB

2020

3

Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France)

Hofman, VÃ©ronique, Benzaquen, Jonathan, Heeke, Simon, Lassalle, Sandra, Poudenx, Michel, Long, Elodie, LantÃ©ri, Elisabeth, Bordone, Olivier, Lespinet, Virginie, Tanga, Virginie, Bonnetaud, Christell

Journal:

Lung Cancer

Year:

2020

File:

PDF, 419 KB

2020

4

Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy

Takada, Kazuki, Takamori, Shinkichi, Yoneshima, Yasuto, Tanaka, Kentaro, Okamoto, Isamu, Shimokawa, Mototsugu, Oba, Taro, Osoegawa, Atsushi, Tagawa, Tetsuzo, Takenoyama, Mitsuhiro, Oda, Yoshinao, Naka

Journal:

Lung Cancer

Year:

2020

File:

PDF, 422 KB

2020

5

Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer

Chen, Vincent, Iwama, Eiji, Kim, In-Kyu, Giaccone, Giuseppe

Journal:

Lung Cancer

Year:

2020

File:

PDF, 1.88 MB

2020

6

Analysis of MET kinase domain rearrangement in NSCLC

Zhuo, Minglei, Liang, Zhen, Yi, Yuting, Wu, Nan, Yang, Xue, Zhong, Jia, Chen, Xiaohan, Huang, Yi, Yu, Zicheng, Liu, Chang, Zeng, Xiaoling, Gu, Wenguang, Zhao, Jun

Journal:

Lung Cancer

Year:

2020

File:

PDF, 2.03 MB

2020

7

Ongoing challenges of using immunotherapy in special populations: Poor performance status patients, elderly patients, and people living with HIV

Gounant, ValÃ©rie, LavolÃ©, Armelle, Quoix, Elisabeth

Journal:

Lung Cancer

Year:

2020

File:

PDF, 201 KB

2020

8

Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience

Rossi, David

Journal:

Lung Cancer

Year:

2020

File:

PDF, 134 KB

2020

9

Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial

Quist, Morten, Langer, Seppo W., Lillelund, Christian, Winther, LÃ¦rke, Laursen, JÃ¸rgen H., Christensen, Karl B., RÃ¸rth, Mikael, Adamsen, Lis

Journal:

Lung Cancer

Year:

2020

File:

PDF, 357 KB

2020

10

Salvage surgery after chemotherapy and/or radiotherapy including SBRT and proton therapy: A consecutive analysis of 38 patients

Kobayashi, Aki K., Horinouchi, Hidehito, Nakayama, Yuko, Ohe, Yuichiro, Yotsukura, Masaya, Uchida, Shinsuke, Asakura, Keisuke, Yoshida, Yukihiro, Nakagawa, Kazuo, Watanabe, Shun-ichi

Journal:

Lung Cancer

Year:

2020

File:

PDF, 573 KB

2020

11

Propensity score adjusted analysis of patients with isolated locoregional recurrence versus de novo locally advanced NSCLC treated with definitive therapy

Friedes, Cole, Mai, Nicholas, Fu, Wei, Hu, Chen, Han, Peijin, Marrone, Kristen A., Voong, K. Ranh, Hales, Russell K.

Journal:

Lung Cancer

Year:

2020

File:

PDF, 1.44 MB

2020

12

Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer

Solomon, Benjamin J., Kim, Elizabeth E., Winter, Maria, Monti, Katherine, Tang, Yiyun, Wilner, Keith D., Wang, Sherry, Ou, Sai-Hong Ignatius

Journal:

Lung Cancer

Year:

2020

File:

PDF, 203 KB

2020

13

Comment on: Jaine et al Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand. Lung Cancer 2018, 124, 233â240. 2018/10/01. DOI: 10.1016/j.lungcan.2018.08.004

Crengle, Sue

Journal:

Lung Cancer

Year:

2020

File:

PDF, 314 KB

2020

14

Corrigendum to â141 â Peptide receptor radionuclide therapy for metastatic bronchopulmonary carcinoid tumours: A single ENETS Centre of Excellence experienceâ [Lung Cancer 127 (Suppl. 1) (January) (2019) S59]

Evans, J., Wang, W.M., Newsom-Davis, T., Sharma, R.

Journal:

Lung Cancer

Year:

2020

File:

PDF, 320 KB

2020

15

Prognostic impact of cancer-associated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma

Yotsukura, Masaya, Asamura, Hisao, Suzuki, Shigeki, Asakura, Keisuke, Yoshida, Yukihiro, Nakagawa, Kazuo, Sakurai, Hiroyuki, Watanabe, Shun-ichi, Motoi, Noriko

Journal:

Lung Cancer

Year:

2020

File:

PDF, 11.22 MB

2020

16

Corrigendum to â167 - An audit of the management of mesothelioma in Southern Englandâ [Lung Cancer 139 (Suppl. 1) (January 2020) S72âS73]

Rudd, P., Pattinson, J., Austin, S., Geldart, T., Bayne, M.

Journal:

Lung Cancer

Year:

2020

File:

PDF, 335 KB

2020

17

High risk, same reward?

Chen, Hanbo, Louie, Alexander V.

Journal:

Lung Cancer

Year:

2020

File:

PDF, 330 KB

2020

18

A reply to âA comment on âLung cancer surgical treatment after solid organ transplantation: a single center 30-year experienceâ

Journal:

Lung Cancer

Year:

2020

File:

PDF, 1.54 MB

2020

20

A reply to âImmune related adverse events and response to immunotherapy: focus on corticosteroids.â

Baldini, Editta, Tibaldi, Carmelo

Journal:

Lung Cancer

Year:

2020

File:

PDF, 113 KB

2020

Volume 145

A cross-modal 3D deep learning for accurate lymph node metastasis prediction in clinical stage T1 lung adenocarcinoma

A modified T categorization for part-solid lesions in Chinese patients with clinical stage I Nonâsmall cell lung cancer

Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France)

Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy

Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer

Analysis of MET kinase domain rearrangement in NSCLC

Ongoing challenges of using immunotherapy in special populations: Poor performance status patients, elderly patients, and people living with HIV

Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience

Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial

Salvage surgery after chemotherapy and/or radiotherapy including SBRT and proton therapy: A consecutive analysis of 38 patients

Propensity score adjusted analysis of patients with isolated locoregional recurrence versus de novo locally advanced NSCLC treated with definitive therapy

Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer

Comment on: Jaine et al Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand. Lung Cancer 2018, 124, 233â240. 2018/10/01. DOI: 10.1016/j.lungcan.2018.08.004

Corrigendum to â141 â Peptide receptor radionuclide therapy for metastatic bronchopulmonary carcinoid tumours: A single ENETS Centre of Excellence experienceâ [Lung Cancer 127 (Suppl. 1) (January) (2019) S59]

Prognostic impact of cancer-associated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma

Corrigendum to â167 - An audit of the management of mesothelioma in Southern Englandâ [Lung Cancer 139 (Suppl. 1) (January 2020) S72âS73]

High risk, same reward?

Contents

A reply to âA comment on âLung cancer surgical treatment after solid organ transplantation: a single center 30-year experienceâ

A reply to âImmune related adverse events and response to immunotherapy: focus on corticosteroids.â